{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:47:12Z","timestamp":1782535632519,"version":"3.54.5"},"reference-count":21,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2016,10,2]],"date-time":"2016-10-02T00:00:00Z","timestamp":1475366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:p>\n                    Ivabradine is a selective I\n                    <jats:sub>f<\/jats:sub>\n                    current inhibitor that is used to lower the heart rate (HR) of patients with angina and\/or heart failure. It is approved for use in several countries, including the United Kingdom, Australia, Saudi Arabia, and the United States. The drug was studied in several clinical trials, and it exhibited beneficial effects on the approved indicators. However, there are some concerns with the safety profile of this drug, especially its effect in reducing HR and causing severe bradycardia. Therefore, the current review assessed the benefit\u2013risk balance of ivabradine. A literature review of the major published studies that assessed the efficacy and safety of ivabradine was performed. The online VigiBase adverse drug reaction (ADR) reporting system was also accessed to investigate reports associated with this drug. A full benefit\u2013risk assessment was performed using the collected data from the above-mentioned resources. Most of the reviewed studies concluded that ivabradine exerted beneficial effects with a tolerable safety profile. Specifically, a favorable benefit\u2013risk profile was found when ivabradine was used for patients with an HR \u226570 beats per minute. Reports revealed that the most common ADR was bradycardia, which was expected. Other safety risks or ADRs were comparable to other prescribed drugs. This review presents an up-to-date analysis of ivabradine from the latest literature and reports. These studies suggest that ivabradine exhibits an acceptable and favorable benefit\u2013risk profile, and this drug should be considered as a viable option in patients with angina pectoris and chronic heart failure.\n                  <\/jats:p>","DOI":"10.1177\/1074248416672008","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T20:08:33Z","timestamp":1475525313000},"page":"210-218","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Ivabradine: Do the Benefits Outweigh the Risks?"],"prefix":"10.1177","volume":"22","author":[{"given":"Thamir M.","family":"Alshammari","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia"},{"name":"Medication Safety Research Chair, King Saud University Riyadh, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,10,2]]},"reference":[{"key":"bibr1-1074248416672008","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666150531152047"},{"key":"bibr2-1074248416672008","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.02.001"},{"key":"bibr3-1074248416672008","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-303375"},{"key":"bibr4-1074248416672008","doi-asserted-by":"publisher","DOI":"10.1016\/S0828-282X(08)71019-5"},{"key":"bibr5-1074248416672008","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.183913"},{"key":"bibr6-1074248416672008","unstructured":"Servier. Ivabradine approval and marketing status. 2015."},{"key":"bibr7-1074248416672008","unstructured":"Ivabradine authorisation details. European Medicines Agency (EMA). http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000597\/human_med_000995.jsp&mid=WC0b01ac058001d124. Updated June 7, 2016. Accessed June 2016."},{"key":"bibr8-1074248416672008","unstructured":"Electronic Medicines Compendium (eMC). Procoralan summary of product characteristics [Internet]. https:\/\/www.medicines.org.uk\/emc\/search\/?q=ivabradine%20hydrochloride&dt=1. Updated June 7, 2016. Accessed June, 2015."},{"key":"bibr9-1074248416672008","unstructured":"AUS Therapeutic Goods Administration (TGA). Medicines Safety Update Volume 6 Number 3, June 2015. Ivabradine and cardiovascular events in patients with angina. 2015. https:\/\/www.tga.gov.au\/publication-issue\/medicines-safety-update-volume-6-number-3-june-2015#ivabr. Updated May 31, 2015. Accessed June, 2015."},{"key":"bibr10-1074248416672008","unstructured":"Food and Drug Administration. Drugs@FDA. Corlanor. Label Information. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206143Orig1s000lbl.pdf. Updated April 15, 2015. Accessed June, 2015."},{"key":"bibr11-1074248416672008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406430"},{"key":"bibr12-1074248416672008","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"bibr13-1074248416672008","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"bibr14-1074248416672008","unstructured":"World Health Organization. VigiAccess\u2122 Ivabradine. 2016. http:\/\/www.vigiaccess.org\/. Updated February 15, 2016. Accessed March, 2016."},{"key":"bibr15-1074248416672008","unstructured":"Food and Drug Administration. Ivabradine label information. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206143Orig1s000lbl.pdf. Updated April 15, 2015. Accessed June, 2015."},{"key":"bibr16-1074248416672008","unstructured":"European Medicines Agency. European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor\/Procoralan (ivabradine). 2015. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Corlentor_and_Procoralan\/human_referral_prac_000044.jsp&mid=WC0b01ac05805c516f. Updated February 16, 2015. Accessed June, 2015."},{"key":"bibr17-1074248416672008","unstructured":"Medicines and Healthcare Products Regulatory Agency. Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects. 2014. https:\/\/www.gov.uk\/drug-safety-update\/ivabradine-procoralan-in-the-symptomatic-treatment-of-angina-risk-of-cardiac-side-effects. Updated December 19, 2014. Accessed June, 2015."},{"key":"bibr18-1074248416672008","unstructured":"Saudi Food and Drug Authority. Ivabradine withdrawal from Saudi Market. 2015. http:\/\/www.sfda.gov.sa\/ar\/drug\/circulations\/Pages\/Drug-circulars-03082010.aspx. Updated May 3, 2015. Accessed June, 2015."},{"key":"bibr19-1074248416672008","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv150"},{"key":"bibr20-1074248416672008","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv190"},{"key":"bibr21-1074248416672008","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.84"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248416672008","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1074248416672008","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248416672008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:42:31Z","timestamp":1777394551000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1074248416672008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,2]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1177\/1074248416672008"],"URL":"https:\/\/doi.org\/10.1177\/1074248416672008","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,2]]}}}